natgillin/translations-raw huggingface dataset:
Thyroid-stimulating hormone (TSH) should be monitored in patients treated with levothyroxine at least the first month after starting and/or ending ritonavir treatment. 
U bolesnika liječenih levotiroksinom potrebno je pratiti tireostimulirajući hormon (TSH) barem prvi mjesec nakon početka i/ili kraja liječenja ritonavirom.
Hepatic changes involved hepatocellular, biliary and phagocytic elements and were accompanied by increases in hepatic enzymes. 
Promjene u jetri uključivale su hepatocelularne, žučne i fagocitne elemente, a bile su praćene porastom vrijednosti jetrenih enzima.
Animal studies do not indicate harmful effects of ritonavir on fertility (see section 5.3). 
Ispitivanja na životinjama ne ukazuju na štetne učinke ritonavira na plodnost (vidjeti dio 5.3).
Saquinavir should only be given in combination with ritonavir. 
Sakvinavir treba davati samo u kombinaciji s ritonavirom.
Patients should be advised to seek medical advice if they experience joint aches and pain, joint stiffness or difficulty in movement. 
Bolesnike treba upozoriti da potraže liječničku pomoć javi li se osjetljivost ili bol u zglobovima, ukočenost zglobova ili otežano kretanje.
People taking ritonavir may still develop infections or other illnesses associated with HIV infection or AIDS. 
- Osobe koje uzimaju ritonavir mogu svejedno razviti infekcije ili druge bolesti povezane s HIVinfekcijom ili s AIDS-om.
Analgesics Buprenorphine 
Analgetici Buprenorfin
Although rifampicin may induce metabolism of ritonavir, limited data indicate that when high doses of ritonavir (600 mg twice daily) is co-administered with rifampicin, the additional inducing effect of rifampicin (next to that of ritonavir itself) is small and may have no clinical relevant effect on ritonavir levels in high-dose ritonavir therapy. 
Premda rifampicin može inducirati metabolizam ritonavira, ograničeni podaci upućuju na to da je pri primjeni ritonavira u velikim dozama (600 mg dva puta na dan) istodobno s rifampicinom dodatni inducirajući učinak rifampicina (povrh učinka samog ritonavira) slab i vjerojatno ne utječe klinički značajno na razine ritonavira pri liječenju velikim dozama ritonavira.
Patients receiving ritonavir or any other antiretroviral therapy may continue to develop opportunistic infections and other complications of HIV-1 infection. 
Bolesnici koji primaju ritonavir ili koji drugi antiretrovirusni lijek mogu i dalje biti skloni pojavi različitih oportunističkih infekcija i ostalih komplikacija koje prate infekciju virusom HIV-1.
Ritonavir is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infected patients (adults and children of 2 years of age and older). 
Ritonavir je, u kombinaciji s drugim antiretrovirusnim lijekovima, indiciran za liječenje bolesnika zaraženih virusom HIV-1 (odraslih i djece u dobi od 2 godine i starije).
Although the aetiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported in patients with advanced HIV-disease and/or long-term exposure to combination antiretroviral therapy (CART). 
Premda se smatra da je etiologija multifaktorijalna (uključujući primjenu kortikosteroida, konzumaciju alkohola, tešku imunosupresiju, veći indeks tjelesne mase), prijavljeni su slučajevi osteonekroze u bolesnika s uznapredovalom HIV-bolešću i/ili onih na dugotrajnom kombiniranom antiretrovirusnom liječenju (CART).
Immunosuppressants Cyclosporine, tacrolimus, everolimus 
Imunosupresivi Ciklosporin, takrolimus, everolimus
No subject experienced an increase in QTcF of ≥ 60 msec from baseline or a QTcF interval exceeding the potentially clinically relevant threshold of 500 msec. 
Ni u jednog ispitanika QTcF-a se nije produžio za više od ≥ 60 msec u odnosu na početnu vrijednost, niti je QTcF-interval premašivao potencijalno klinički značajni prag od 500 msec.
0.125, single dose 
0,125, jednokratna doza
PHARMACEUTICAL FORM AND CONTENTS Film-coated tablets 
OBLIK I SADRŽAJ Filmom obložene tablete
The use of higher ritonavir doses may alter the safety profile of atazanavir (cardiac effects, hyperbilirubinemia) and therefore is not recommended. 
Primjena ritonavira u većim dozama može promijeniti profil neškodljivosti atazanavira (učinci na srce, hiperbilirubinemija) i stoga se ne preporučuje.
• increase in cholesterol 
• povišen kolesterol
• increase in triglycerides 
• povišeni trigliceridi
SPECIAL STORAGE CONDITIONS Do not store above 30C. 
POSEBNE MJERE ČUVANJA Ne čuvati na temperaturi iznad 30 °C.
developing viral resistance (in HIV-postive infants) and (3) serious adverse reactions in a breastfed infant, HIV infected women should not breast feed their infants under any circumstances if they are receiving ritonavir. 
Zbog mogućnosti (1) prijenosa HIV-a (u HIV-negativne dojenčadi), (2) razvoja virusne rezistencije (u HIV-pozitivne dojenčadi) i (3) pojave ozbiljnih nuspojava u dojenčadi, žene zaražene HIV-om ne smiju ni pod kojim uvjetima dojiti svoju djecu ako primaju ritonavir.
Multipack: 90 (3 bottles of 30) film-coated tablets 
Višestruko pakiranje: 90 (3 bočice po 30) filmom obloženih tableta
After ritonavir use for 10 days, no inhibitory effect of ritonavir was observed. 
Nakon primjene ritonavira tijekom 10 dana više nije bilo inhibicijskog učinka.
(For caution on parenterally administered midazolam, see section 4.5. 
(Za mjere opreza pri parenteralnoj primjeni midazolama vidjeti dio 4.5).
10, single dose 600q12h ↑ 153% ↑ 55% Inhibition of CYP3A and P-gp lead to increased plasma levels and pharmacodynamic effects of rivaroxaban which may lead to an increased bleeding risk. 
10, jednokratna doza 600 svakih12 h ↑ 153% ↑ 55% Inhibicija CYP3A i P-gp je rezultirala povećanjem razina u plazmi te povećanjem farmakodinamičkog učinka rivaroksabana što može dovesti do povećanog rizika od krvarenja.
Hormonal contraceptives containing ethinylestradiol as ritonavir may reduce the effectiveness of these medicines. 
- Hormonski kontraceptivi koji sadržavaju etinilestradiol, jer ritonavir može smanjiti učinkovitost tih lijekova.
Ritonavir concentrations in this study were highly variable and somewhat lower than those obtained in adults receiving 600 mg (approximately 330 mg/m2) twice daily. 
Koncentracije ritonavira u tom su istraživanju bile vrlo varijabilne i nešto niže od onih izmjerenih u odraslih koji su primali 600 mg (oko 330 mg/m²) dva puta na dan.
Dose adjustment should be considered based on the patient's clinical response to methadone therapy. 
Dozu treba prilagođavati ravnajući se bolesnikovim kliničkim odgovorom na primjenu metadona.
• flushing, feeling hot 
• navale crvenila, osjećaj vrućine
The most frequently used nucleosides in this study were zidovudine, stavudine, didanosine and zalcitabine. 
Najčešće korišteni nukleozidi u tom ispitivanju bili su zidovudin, stavudin, didanozin i zalcitabin.
A dose reduction of the glucocorticoid should be considered with close monitoring of local and systemic effects or a switch to a glucocorticoid, which is not a substrate for CYP3A4 (e.g., beclomethasone). 
Valja razmotriti smanjivanje doze glukokortikoida i pažljivo pratiti lokalne i sistemne učinke, ili prijeći na primjenu glukokortikoida koji nije supstrat enzima CYP3A4 (npr. beklometazon).
Medicinal product interactions - Ritonavir with protease inhibitors 
Interakcije lijekova - ritonavir s inhibitorima proteaza
Ritonavir Mylan should be administered by physicians who are experienced in the treatment of HIV infection. 
Ritonavir Mylan moraju davati liječnici iskusni u liječenju HIV infekcije.
Norbuprenorphine Glucuronide metabolites 
Norbuprenorfin Glukuronidni metaboliti
Based on comparison to historical data, the pharmacokinetics of delavirdine did not appear to be affected by ritonavir. 
Na temelju usporedbe s povijesnim podacima, čini se da ritonavir ne utječe na farmakokinetiku delavirdina.
The effects of ritonavir (alone or combined with other antiretroviral agents) on biological markers of disease activity such as CD4 cell count and viral RNA were evaluated in several studies involving HIV-1 infected patients. 
Učinci ritonavira (samog ili u kombinaciji s drugim antiretrovirusnim lijekovima) na biološke biljege bolesti, poput broja CD4 stanica i virusne RNA, evaluirani su u nekoliko ispitivanja provedenih u bolesnika s HIV-1 infekcijama.
Talk to your doctor before you take any cholesterol-reducing medicines with ritonavir (see also ‘Do not take Ritonavir Mylan' above). 
Porazgovarajte sa svojim liječnikom prije nego počnete uzimati bilo koji lijek za sniženje kolesterola i ritonavir (pogledajte i „Nemojte uzimati Ritonavir Mylan” u tekstu gore).
Patients with pre-existing liver dysfunction including chronic active hepatitis have an increased frequency of liver function abnormalities during combination antiretroviral therapy and should be monitored according to standard practice. 
U bolesnika s već prisutnom disfunkcijom jetre, uključujući kronični aktivni hepatitis, povećana je učestalost poremećaja jetrene funkcije tijekom kombiniranog antiretrovirusnog liječenja te takve bolesnike treba pratiti u skladu sa standardnom praksom.
Anticonvulsants Carbamazepine 
Antikonvulzivi Karbamazepin
↔ ↑ 4 fold 
↔ ↑ 4 puta
Ritonavir has been shown to cause modest asymptomatic prolongation of the PR interval in some healthy adult subjects. 
Pokazalo se da ritonavir uzrokuje umjereno asimptomatsko produženje PR-intervala u nekih zdravih ispitanika.
These data largely refer to exposures where ritonavir was used in combination therapy and not at therapeutic ritonavir doses but at lower doses as a pharmacokinetic enhancer for other PIs. 
Ti se podaci pretežno odnose na slučajeve u kojima se ritonavir davao u kombinaciji s drugim lijekom, ne u terapijskim dozama već u manjim dozama, kao pojačivač farmakokinetike drugih IP.
If ritonavir is co-administered with parenteral midazolam, it should be done in an intensive care unit (ICU) or similar setting which ensures close clinical monitoring and appropriate medical management in case of respiratory depression and/or prolonged sedation. 
Ako se ritonavir daje istodobno s parenteralnim midazolamom, to treba činiti u jedinici za intenzivnu skrb (intensive care unit, ICU) ili u sličnim uvjetima u kojima je moguće pažljivo kliničko praćenje i pružanje primjerene skrbi u slučaju depresije dišnog sustava i/ili produžene sedacije.
PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING BOTTLE LABEL OF MULTIPACK (WITHOUT BLUE BOX) 
PODACI KOJI SE MORAJU NALAZITI NA UNUTARNJEM PAKIRANJU NALJEPNICA NA BOČICI MULTIPAKIRANJA (BEZ PLAVE KUTIJE)
200 daily 
200 na dan
Due to the solubility characteristics and possibility of transintestinal elimination, it is proposed that management of overdose could entail gastric lavage and administration of activated charcoal. 
Zbog karakteristika topivosti i mogućnosti transintestinalne eliminacije, predlaže se da liječenje predoziranja uključuje i ispiranje želuca te primjenu aktivnog ugljena.
Tablet dose 
Doza tableta
However, clinical trials revealed no evidence of medicinal product-induced ocular changes in humans. 
No u kliničkim ispitivanjima nije bilo dokaza o lijekom induciranim promjenama na oku čovjeka.
0.5 single IV dose 
0,5 jednokratne iv. doze
Serious persistent vomiting and/or diarrhoea associated with ritonavir use might also compromise renal function. 
Ozbiljno i ustrajno povraćanje i/ili proljev, povezani s primjenom ritonavira, mogu oslabiti i funkciju bubrega.
When used in combination with delavirdine, dose reduction of ritonavir may be considered. 
Pri primjeni u kombinaciji s delavirdinom, možda će trebati razmotriti smanjenje doze ritonavira.
For older children it may be feasible to substitute tablets for the maintenance dose of other pharmaceutical forms. 
U starije se djece može pokazati prikladnim da se drugi farmaceutski oblici nakon prelaska na dozu održavanja zamijene tabletama.
Also tell your doctor if you experience joint stiffness, aches and pains (especially of the hip, knee and shoulder) and difficulty moving, as this may be a sign of osteonecrosis. 
Također kažite liječniku ako se jave ukočenost i tupi bolovi i probadanje u zglobovima (osobito u kuku, koljenu ili ramenu) i otežano kretanje jer to mogu biti znakovi osteonekroze.
The recommended dose of ritonavir is 600 mg (6 tablets) twice daily (total of 1,200 mg per day) by mouth. 
Preporučena doza ritonavira je 600 mg (šest tableta) dva puta na dan kroz usta (ukupno 1200 mg na dan).
Hepatitis (including increased AST, ALT, GGT), blood bilirubin increased (including jaundice) 
Hepatitis (uključujući povišenje AST-a, ALT-a i GGT-a), povišenje bilirubina u krvi (uključujući žuticu)
In cases of co-administration of ritonavir (100 mg twice daily) and indinavir (800 mg twice daily) caution is warranted as the risk of nephrolithiasis may be increased. 
U slučajevima istodobne primjene ritonavira (100 mg dva puta na dan) i indinavira (800 mg dva puta na dan) savjetuje se oprez jer zbog povećanog rizika od nefrolitijaze.
In addition to the interactions listed above, as ritonavir is highly protein bound, the possibility of increased therapeutic and toxic effects due to protein binding displacement of concomitant medicinal products should be considered. 
Osim gore navedenih interakcija, budući da se ritonavir u visokom stupnju veže na proteine, treba imati na umu i mogućnost pojačanih terapijskih i toksičnih učinaka zbog istiskivanja na proteine vezanih lijekova primijenjenih istodobno s ritonavirom.
Pancreatitis should be considered if clinical symptoms (nausea, vomiting, abdominal pain) or abnormalities in laboratory values (such as increased serum lipase or amylase values) suggestive of pancreatitis should occur. 
Prisutnost pankreatitisa treba razmotriti ako se jave klinički simptomi (mučnina, povraćanje, bol u trbuhu) ili abnormalni nalazi laboratorijskih pretraga (npr. povišena vrijednost serumske lipaze ili amilaze) koji upućuju na pankreatitis.
Based on interaction studies with the ritonavir boosted protease inhibitors (lopinavir/ritonavir, atazanavir), concurrent administration of omeprazole or ranitidine does not significantly modify ritonavir efficacy as a pharmacokinetic enhancer despite a slight change of exposure (about 6 - 18%). 
Na temelju ispitivanja interakcija inhibitora proteaza pospješenih ritonavirom (lopinavir/ritonavir, atazanavir), pri istodobnoj primjeni omeprazola ili ranitidina ne mijenja se značajno učinkovitost ritonavira kao farmakokinetičkog pojačivača, unatoč blagoj promjeni izloženosti (za oko 6% - 18%).
If you take more Ritonavir Mylan than you should 
Ako uzmete više lijeka Ritonavir Mylan nego što ste trebali
However, because ritonavir has also been shown to inhibit CYP2B6 in vitro, the recommended dose of bupropion should not be exceeded. 
No kako se pokazalo da ritonavir i inhibira aktivnost CYP2B6 in vitro, ne smije se premašiti preporučena doza bupropiona.
Antiasthmatic Theophylline1 
Antiastmatici Teofilin1
The following HIV-1 protease inhibitors have been approved for use with ritonavir as a pharmacokinetic enhancer at the noted doses. 
Sljedeći su inhibitori proteaza virusa HIV-1 odobreni za primjenu u kombinaciji s ritonavirom kao farmakokinetičkim pojačivačem u navedenim dozama.
Cases of osteonecrosis have been reported, particularly in patients with generally acknowledged risk factors, advanced HIV disease or long-term exposure to combination antiretroviral therapy (CART). 
Prijavljeni su slučajevi osteonekroze, osobito u bolesnika s općepoznatim čimbenicima rizika, uznapredovalom HIV-infekcijom i u bolesnika na dugotrajnom kombiniranom antiretrovirusnom liječenju (CART).
The inducing effect may persist for at least 2 weeks after cessation of treatment with St John's wort (see section 4.3). 
Inducirajući učinak može potrajati najmanje 2 tjedna nakon prekida uzimanja gospine trave (vidjeti dio 4.3).
Do not use this medicine after the expiry date on the carton or bottle label after ‘EXP'. 
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji ili naljepnici bočice iza oznake „Rok valjanosti”.
Induction of CYP1A2 and CYP2C9 lead to decreased levels of R-warfarin while little pharmacokinetic effect is noted on S-warfarin when co-administered with ritonavir. 
Zbog indukcije CYP1A2 i CYP2C9 snižavaju se razine R-varfarina, dok je na S-varfarin uočen tek slab farmakokinetički učinak pri istodobnoj primjeni s ritonavirom.
Ritonavir is a protease inhibitor used to control HIV infection. 
Ritonavir je inhibitor proteaza koji se koristi za kontrolu HIV-infekcije.
Particular caution should be used when prescribing sildenafil or tadalafil for the treatment of erectile dysfunction in patients receiving ritonavir. 
Poseban je oprez nužan pri propisivanju sildenafila ili tadalafila za liječenje erektilne disfunkcije bolesnicima koji primaju ritonavir.
Therefore, the use of ritonavir is not recommended in patients receiving rivaroxaban. 
Stoga se ne preporučuje primjena ritonavira kod bolesnika koji uzimaju rivaroksaban.
Ergot derivatives 
Derivati ergota
For patients who have completed the ramp-up phase and are on a steady daily dose of venetoclax, reduce the venetoclax dose by at least 75% when used with strong CYP3A inhibitors (refer to the venetoclax SmPC for dosing instructions). 
U bolesnika koji su završili razdoblje povećavanja doze i koji primaju stabilnu dnevnu dozu venetoklaksa, dozu venetoklaksa treba smanjiti za najmanje 75% pri istodobnoj primjeni sa snažnim inhibitorima CYP3A (za upute za doziranje vidjeti Sažetak opisa svojstava lijeka za venetoklaks).
The mean average change from baseline over 16 weeks for HIV RNA levels was -0.79 log10 (maximum mean decrease: 1.29 log10) in the ritonavir group versus -0.01 log10 in the control group. 
Srednja prosječna promjena razina HIV RNA nakon 16 tjedana u odnosu na početno stanje iznosila je −0,79 log10 (maksimalno srednje smanjenje: 1,29 log10) u skupini liječenoj ritonavirom, u usporedbi s −0.01 log10 u kontrolnoj skupini.
There are some medicines you cannot take at all with ritonavir. 
Neke lijekove nikako ne smijete uzimati s ritonavirom.
Ritonavir Mylan can cause dizziness. 
Ritonavir Mylan može izazvati omaglicu.
Renal clearance averaged less than 0.1 l/h and was relatively constant throughout the dosage range. 
Bubrežni je klirens iznosio prosječno manje od 0,1 l/h i bio je razmjerno konstantan u cijelom rasponu doza.
Diabetes, as there have been reports of worsening of or the development of diabetes (diabetes mellitus) in some patients taking protease inhibitors. 
- Šećernu bolest, jer je bilo prijava pogoršanja ili razvoja šećerne bolesti (dijabetes melitus) u nekih bolesnika koji su uzimali inhibitore proteaza.
Abdominal pain (upper and lower), nausea, diarrhoea (including severe with electrolyte imbalance), vomiting, dyspepsia 
Vrlo često Bol u gornjem i donjem abdomenu, mučnina, proljev (uključujući teški proljev s elektrolitskim disbalansom), povraćanje, dispepsija
Dose of ritonavir (mg) 
Doza ritonavira (mg)
Increased amylase, decreased free and total thyroxin 
Povišena vrijednost amilaze, snižene vrijednosti slobodnog i ukupnog tiroksina
• inflammation of the liver and yellowing of skin or whites of the eyes 
• upala jetre i žuta boja kože ili bjeloočnica
If treatment with an HMGCoA reductase inhibitor is indicated, pravastatin or fluvastatin is recommended (see section 4.5). 
Ako je indicirano liječenje inhibitorom HMG-CoA reduktaze, preporučuju se pravastatin ili fluvastatin (vidjeti dio 4.5).
Also, the side effects of ritonavir when used with other antiretroviral medicines are dependent on the other medicines. 
Uz to, nuspojave ritonavira, kada se koristi s drugim antiretrovirusnim lijekovima, ovise i o tim drugim lijekovima.
If you realise you have taken more Ritonavir Mylan than you were supposed to, contact your doctor or the Accident and Emergency Department of your nearest hospital straight away. 
Ako shvatite da ste uzeli više lijeka Ritonavir Mylan nego što je trebalo, javite se odmah svome liječniku ili hitnoj službi najbliže bolnice.
If trazodone is co-administered with ritonavir, the combination should be used with caution, initiating trazodone at the lowest dosage and monitoring for clinical response and tolerability. 
Ako se trazodon daje istodobno s ritonavirom, tu kombinaciju treba davati oprezno, a trazodon treba početi davati u najmanjoj dozi te pratiti klinički odgovor i podnošljivost.
Maximal inhibition of metabolism of the co-administered protease inhibitor is generally achieved with ritonavir doses of 100 mg daily to 200 mg twice daily, and is dependent on the co-administered protease inhibitor. 
Maksimalna inhibicija metabolizma istodobno primijenjenog inhibitora proteaza općenito se postiže dozama ritonavira od 100 mg na dan do 200 mg dva puta na dan i ovisi o istodobno primijenjenom inhibitoru proteaza.
Ritonavir-resistant isolates of HIV-1 have been selected in vitro and isolated from patients treated with therapeutic doses of ritonavir. 
Izolati virusa HIV-1 rezistentni na ritonavir nađeni su in vitro, i izdvojeni od bolesnika liječenih terapijskim dozama ritonavira.
As ritonavir is recommended to be taken with food and didanosine should be taken on an empty stomach, dosing should be separated by 2.5 h. Dose alterations should not be necessary. 
Budući da se preporučuje uzimanje ritonavira s hranom, a didanozin se mora uzimati na prazan želudac, između uzimanja dvaju lijekova treba načiniti razmak od 2,5 sata.
The maximum daily dose of this product is equivalent to 53% of the WHO recommended maximum daily intake for sodium. 
Maksimalna dnevna doza ovog lijeka iznosi 53% maksimalnog dnevnog unosa natrija prema preporukama SZO-a.
Patients with advanced HIV disease may be at risk of elevated triglycerides and pancreatitis (see section 4.4). 
Bolesnici s uznapredovalom HIV bolesti mogu biti izloženi većem riziku od povišenja razine triglicerida i pankreatitisa (vidjeti dio 4.4).
Paediatric population (2 years of age and above) The recommended dosage of ritonavir in children is 350 mg/m2 by mouth twice daily and should not exceed 600 mg twice daily. 
Pedijatrijska populacija (u dobi od 2 godine i stariji) Preporučena doza ritonavira u djece je 350 mg/m² dva puta na dan kroz usta, a doza ne smije premašiti 600 mg dva puta na dan.
Ritonavir is likely to change the uterine bleeding profile and reduce the effectiveness of estradiol-containing contraceptives (see section 4.4). 
Ritonavir vjerojatno mijenja profil uterinog krvarenja i smanjuje učinkovitost kontraceptiva koji sadržavaju estradiol (vidjeti dio 4.4).
Endothelin antagonists Bosentan 
Antagonisti endotelinskih receptora Bosentan
In patients who are already taking digoxin when ritonavir is introduced, the digoxin dose should be reduced to one-half of the patients' normal dose and patients need to be followed more closely than usual for several weeks after initiating co-administration of ritonavir and digoxin. 
Kada se ritonavir uvodi bolesnicima koji već uzimaju digoksin, dozu digoksina treba smanjiti na polovinu uobičajene, a bolesnike treba pratiti pažljivije nego inače nekoliko tjedana nakon početka istodobne primjene ritonavira i digoksina.
Steroids (e.g. dexamethasone, fluticasone propionate, prednisolone, triamcinolone) as ritonavir may raise the blood levels of these medicines which may lead to Cushing's syndrome (development of a rounded face) and reduce production of the hormone cortisol. 
- Steroidi (npr. deksametazon, flutikazonpropionat, prednizolon, triamcinolon), jer ritonavir može povisiti razine tih lijekova u krvi, što može izazvati pojavu Cushingova sindroma (stvaranje okruglog lica) i smanjiti stvaranje hormona kortizola.
Ultrastructural evidence suggests that these retinal changes may be secondary to phospholipidosis. 
Ultrastrukturna analiza upućuje na to da bi promjene na mrežnici mogle biti posljedica fosfolipidoze.
Caution must also be exercised and reduced doses should be considered if ritonavir is used concurrently with atorvastatin, which is metabolised to a lesser extent by CYP3A. 
Nužan je oprez, te treba razmotriti i smanjivanje doze ako se ritonavir daje istodobno s atorvastatinom, koji se u manjoj mjeri metabolizira putem CYP3A.